ACCELERATE study with CETP inhibitor extended by 6 months
News - Feb. 20, 2015
The ACCELERATE study academic executive committee recommended, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months. The recommendation is not based on any data from ACCELERATE, as both the academic committee and the company remain blinded to efficacy results.
Last patient visit in ACCELERATE – which is evaluating evacetrapib in approximately 12,000 people with high-risk atherosclerotic cardiovascular disease (ASCVD) -- is now expected in July 2016.
The academic executive committee based its recommendation on analysis of recent results from other drugs being studied to reduce major adverse cardiovascular events (MACE). Both the committee and Lilly believe longer treatment will allow appropriate testing of the ACCELERATE hypothesis: that evacetrapib added to statins can reduce MACE events compared to statins alone in patients with ASCVD.
As part of the study extension, a futility analysis previously anticipated in Q1 2015 is now expected to occur in Q3 2015.
The phase, 3, double blind, placebo-controlled trial will include 12,095 patients with high-risk atherosclerotic CVD enrolled at 540 sites in 37 countries. The primary outcome is time to first incidence of CV events including MI, stroke, coronary revascularization, hospitalization due to unstable angina or CV-related death, according to study details on ClinicalTrials.gov.
See press release Eli Lilly and Company
Last patient visit in ACCELERATE – which is evaluating evacetrapib in approximately 12,000 people with high-risk atherosclerotic cardiovascular disease (ASCVD) -- is now expected in July 2016.
The academic executive committee based its recommendation on analysis of recent results from other drugs being studied to reduce major adverse cardiovascular events (MACE). Both the committee and Lilly believe longer treatment will allow appropriate testing of the ACCELERATE hypothesis: that evacetrapib added to statins can reduce MACE events compared to statins alone in patients with ASCVD.
As part of the study extension, a futility analysis previously anticipated in Q1 2015 is now expected to occur in Q3 2015.
The phase, 3, double blind, placebo-controlled trial will include 12,095 patients with high-risk atherosclerotic CVD enrolled at 540 sites in 37 countries. The primary outcome is time to first incidence of CV events including MI, stroke, coronary revascularization, hospitalization due to unstable angina or CV-related death, according to study details on ClinicalTrials.gov.
See press release Eli Lilly and Company
Facebook Comments